Epstein-Barr Virus Induces Adhesion Receptor CD226 (DNAM-1) Expression during Primary B-Cell Transformation into Lymphoblastoid Cell Lines
暂无分享,去创建一个
Dereje D. Jima | S. Dave | M. Luftig | J. Dai | P. Nikitin | Chris Chang | Lisa V Grossman
[1] A. Letai,et al. Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection , 2017, eLife.
[2] Jeffrey T Leek,et al. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.
[3] Manolis Kellis,et al. The NF-κB genomic landscape in lymphoblastoid B cells. , 2014, Cell reports.
[4] M. Smyth,et al. DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins , 2014, Immunology and cell biology.
[5] Amy M. Holthaus,et al. Epstein–Barr Virus Nuclear Antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A , 2013, Proceedings of the National Academy of Sciences.
[6] S. Dave,et al. Analysis of Epstein-Barr Virus-Regulated Host Gene Expression Changes through Primary B-Cell Outgrowth Reveals Delayed Kinetics of Latent Membrane Protein 1-Mediated NF-κB Activation , 2012, Journal of Virology.
[7] John Quackenbush,et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth , 2011, Proceedings of the National Academy of Sciences.
[8] M. Rowe,et al. Epstein-Barr Virus Infection of Polarized Epithelial Cells via the Basolateral Surface by Memory B Cell-Mediated Transfer Infection , 2011, PLoS pathogens.
[9] S. Dave,et al. An ATM/Chk2-mediated DNA damage responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells , 2010, Infectious Agents and Cancer.
[10] M. Luftig,et al. MDM2-dependent inhibition of P53 is required for Epstein-Barr virus B cell growth transformation and infected cell survival , 2009, Infectious Agents and Cancer.
[11] G. Bornkamm,et al. Epstein‐Barr virus and the pathogenesis of Burkitt's lymphoma: More questions than answers , 2009, International journal of cancer.
[12] L. Staudt,et al. c-Myc and Rel/NF-κB Are the Two Master Transcriptional Systems Activated in the Latency III Program of Epstein-Barr Virus-Immortalized B Cells , 2009, Journal of Virology.
[13] J. Gutkind,et al. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer , 2008, Oncogene.
[14] A. Rickinson,et al. Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.
[15] Y. Zhang,et al. Identification and Characterization of the CD226 Gene Promoter* , 2006, Journal of Biological Chemistry.
[16] S. Honda,et al. LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell. , 2006, International immunology.
[17] A. Shibuya,et al. Requirement of the serine at residue 329 for lipid raft recruitment of DNAM-1 (CD226). , 2005, International immunology.
[18] L. Moretta,et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. , 2005, Molecular immunology.
[19] J. Cohen,et al. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] Lewis L Lanier,et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). , 2004, International immunology.
[21] D. Thorley-Lawson,et al. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.
[22] F. Luscinskas,et al. Regulation of Leukocyte Transmigration: Cell Surface Interactions and Signaling Events 1 , 2004, The Journal of Immunology.
[23] E. Kieff,et al. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[24] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[25] Gunther Hartmann,et al. Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 , 2000, The Journal of Immunology.
[26] G. Mosialos,et al. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB , 1999, Oncogene.
[27] M. Kersten,et al. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. , 1998, Leukemia & lymphoma.
[28] Jaap M Middeldorp,et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. , 1997, Journal of clinical pathology.
[29] T. Mcclanahan,et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.
[30] W. Newman,et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. , 1994, Journal of immunology.
[31] A. Rickinson,et al. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes , 1992, Journal of virology.
[32] P. Lipsky,et al. The role of CD11a/CD18-CD54 interactions in human T cell-dependent B cell activation. , 1991, Journal of immunology.
[33] G. M. Taylor,et al. Expression of LFA‐1 by a lymphoblastoid cell line from a patient with monosomy 21: effects on intercellular adhesion , 1990, Clinical and experimental immunology.
[34] E. Kieff,et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. , 1989, The New England journal of medicine.
[35] L. Young,et al. Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.
[36] Michael Loran Dustin,et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.
[37] Feng Zhang,et al. Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.
[38] Jaap M Middeldorp,et al. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. , 2003, Critical reviews in oncology/hematology.
[39] G. Mosialos,et al. Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. , 1999, Oncogene.
[40] Michael Loran Dustin,et al. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. , 1987, Annual review of immunology.